Autor(es): de Paula-Silva, Marina ; da Rocha, Gustavo Henrique Oliveira ; Broering, Milena Fronza ; Queiroz, Maria Luíza ; Sandri, Silvana ; Loiola, Rodrigo Azevedo ; Oliani, Sonia Maria [UNESP] ; Vieira, Andrea ; Perretti, Mauro ; Farsky, Sandra Helena Poliselli
Data: 2022
Identificador Persistente: http://hdl.handle.net/11449/229642
Origem: Oasisbr
Assunto(s): annexin A1; biomarkers; Crohn’s disease; dextran sodium sulfate; formyl peptide receptor; infliximab
Made available in DSpace on 2022-04-29T08:34:56Z (GMT). No. of bitstreams: 0 Previous issue date: 2021-09-17
Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)
Non-responsiveness to anti-TNF-α therapies presents relevant rates in inflammatory bowel disease patients, presenting the need to find biomarkers involved in therapeutic efficacy. Herein, we demonstrate that higher levels of colonic formyl peptide receptor 1 and annexin A1 correlate with histological recovery in Crohn’s disease patients under remission. Using the dextran sulfate sodium colitis model in mice, we suggest that infliximab induces annexin A1 expression and secretion in activated intestinal leukocytes. Conversely, this mechanism might stimulate epithelial formyl peptide receptors, inducing wound healing and consequent histological remission. Our data indicate that assessing intestinal expressions of formyl peptide receptors and annexin A1 might provide precious information on the disease activity and responsiveness to infliximab in inflammatory bowel disease patients.
Department of Clinical and Toxicological Analyses University of São Paulo (USP)
Centre for Biochemical Pharmacology The William Harvey Research Institute The London School of Medicine
Gastroenterology Service Irmandade da Santa Casa de Misericórdia de São Paulo
Department of Biology São Paulo State University (UNESP) São José do Rio Preto
Department of Biology São Paulo State University (UNESP) São José do Rio Preto
